Atara Biotherapeutics (NASDAQ:ATRA) announces updated results from an ongoing Phase 1 clinical trial evaluating lead candidate ATA188 in patients with progressive forms of multiple sclerosis (MS). The data are being presented virtually at the joint ACTRIMS-ECTRIMS Meeting.
Participants in the four cohorts showing sustained disability improvement (SDI) at month 6 maintained improvement through month 12. In addition, a dose-related increase in the number of patients with SDI at month 12 was observed (42% in cohorts 3&4 versus 17% in cohorts 1&2).
Data from the open-label extension with redosing at month 12 showed that all three patients who achieved SDI at that time point maintained SDI at month 15 while one maintained SDI at month 18 and another at month 24.
ATA188 is an allogeneic Epstein-Barr virus (EBV) cytotoxic T lymphocyte immunotherapy that targets EBV antigens that the company believes play a key role in the treatment of MS.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.